Evidence map›Paper›PMID 40673793›Full record

ArticleJournal of extracellular vesicles2025

Yujie Pan, Xianteng Yang, Zhirui Zeng, Futao Liu, Jin Luo, Mao Shen, Wei Zhou, Jianyang Li, Guangfu Jiang, Li Sun and 2 more

Abstract read
In one paragraph

Article in Journal of extracellular vesicles, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yujie PanDepartment of Trauma Centre, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
Xianteng YangDepartment of Orthopedics, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China.
Zhirui ZengEngineering Research Center of Chronic Disease Diagnosis and Treatment, School of Basic Medicine, Guizhou Medical University, Guiyang, Guizhou, China.
Futao LiuDepartment of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, China.
Jin LuoDepartment of Trauma Centre, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
Mao ShenDepartment of Orthopedics, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
Wei ZhouDepartment of Orthopedics, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China.
Jianyang LiDepartment of Orthopedics, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China.
Guangfu JiangDepartment of Orthopedics, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China.
Li SunDepartment of Orthopedics, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China.
Haifeng HuangDepartment of Orthopedics, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China.
Runsang PanDepartment of Orthopedics, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China.ORCID https://orcid.org/0000-0002-8573-8789

Funding

the Guizhou Provincial Science and Technology Projects [2021]395the Guizhou Provincial Science and Technology Projects [2024]168the Guizhou Provincial Science and Technology Projects [2024]481the National Natural Science Foundation of China 82060491the National Natural Science Foundation of China 82160568
6 · The paper itself

Abstract

Metastasis constitutes the principal factor leading to the unfavourable prognosis of osteosarcoma patients. Hypoxia, as the inherent microenvironment of osteosarcoma, can upregulate HIF-1α via multiple pathways, thereby facilitating osteosarcoma proliferation and metastasis. Our previous research indicated that the inwardly rectifying potassium channel subfamily J member 2 (KCNJ2) inhibits the degradation of HIF-1α in osteosarcoma. Concurrently, HIF-1α upregulates the expression of KCNJ2 through a positive feedback regulatory mechanism. This positive regulatory mechanism significantly promotes the proliferation and metastasis of osteosarcoma. Therefore, the development of a KCNJ2-targeted therapeutic strategy capable of disrupting this reciprocal regulatory loop represents a crucial intervention for impeding osteosarcoma progression. The CRISPR/Cas9 targeted gene editing technology has garnered extensive attention in the field of tumour treatment due to its high efficiency and low off-target rate. Nevertheless, the relative lag of the delivery systems has restricted its application. The extracellular vesicles (EVs) secreted by bone marrow mesenchymal stem cells (BMSCs) have a natural targeting specificity for osteosarcoma and possess superior biocompatibility, making them ideal carriers for in vivo delivery. However, it is essential to confirm whether the CRISPR/Cas9 system mediated by EVs can accurately function intracellularly. Hence, we developed a fluorescence-based Cas9 editing efficiency reporter system. When CRISPR/Cas9 system induces double-strand breaks at specific target sites and results in frameshift mutations, osteosarcoma cells will stably express GFP. This system enables the transformation of gene editing events into quantifiable fluorescence signals. Furthermore, we engineered radiolabelled EVs derived from BMSCs to deliver the CRISPR/Cas9 system targeting KCNJ2. Using this reporter system, we confirmed their efficient gene-editing capabilities in vitro. Additionally, leveraging their radiolabelling properties, we validated their targeted distribution in vivo. Subsequent investigations revealed that our constructed

Indexed as

Bone NeoplasmsCRISPR-Cas SystemsExtracellular VesiclesMesenchymal Stem CellsOsteosarcomaRibonucleoproteinsAnimalsCell Line, TumorCell ProliferationGene EditingGreen Fluorescent ProteinsHumansIodine RadioisotopesMiceMice, NudeNeoplasm MetastasisGreen Fluorescent ProteinsIodine RadioisotopesRibonucleoproteinsbone marrow mesenchymal stem cellsCRISPR‐Cas9extracellular vesiclesosteosarcoma

Identifiers

PMID40673793
PMCPMC12269339

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.